A recent study published in The Lancet highlights the alarming financial burden of drug-resistant bacteria in India, revealing that treatment costs can range from Rs 70,000 to Rs 5 lakh. The research underscores the growing threat posed by antimicrobial resistance (AMR), which not only complicates treatment but also leads to increased mortality rates.
The study emphasizes that the economic impact of drug-resistant infections is significant, affecting both healthcare systems and individual patients. The findings indicate that the financial strain is particularly acute for low and middle-income families, who may find it challenging to afford the necessary treatments.
Moreover, the research calls for urgent action from policymakers to address the rise of AMR, recommending improved surveillance, better access to antibiotics, and enhanced infection prevention strategies. The study serves as a wake-up call to the public health community about the critical need for coordinated efforts to combat this growing threat.
Source: news.google.com